Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    51,058.79
    +265.72 (+0.52%)
     

  • CMC Crypto 200

    1,331.60
    +54.62 (+4.28%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
BRANDS:

Meet one of the UK’s largest unknown start-ups

Video editing platform Veed has grown to 10 million users

Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

Amedisys (AMED) reported $571.41 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 2.7%. EPS of $1.03 for the same period compares to $1.00 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $564.58 million, representing a surprise of +1.21%. The company delivered an EPS surprise of +1.98%, with the consensus EPS estimate being $1.01.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Amedisys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Service Revenue- Home health: $364 million versus the two-analyst average estimate of $358.15 million. The reported number represents a year-over-year change of +6%.

  • Net Service Revenue- High Acuity Care: $6.40 million versus $6.20 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +36.2% change.

  • Net Service Revenue- Hospice: $201 million versus the two-analyst average estimate of $202.55 million. The reported number represents a year-over-year change of +3.9%.

View all Key Company Metrics for Amedisys here>>>

Shares of Amedisys have returned -1.2% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amedisys, Inc. (AMED) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research